• Actuate reported publication of randomized Phase 2 trial results in Nature Medicine for elraglusib with standard first-line chemotherapy in previously untreated metastatic pancreatic ductal adenocarcinoma.
• Data were already presented via peer-reviewed publication, showing improved survival outcomes versus chemotherapy alone.
• Survival benefit held in poorer-prognosis subgroups, supporting potential differentiation in a setting with limited progress from immunotherapies.
• Study findings also pointed to an immunomodulatory effect, suggesting a broader combination strategy beyond chemotherapy backbones.
• Safety profile was described as generally manageable, reducing near-term execution risk for continued clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604140845PRIMZONEFULLFEED9689371) on April 14, 2026, and is solely responsible for the information contained therein.